规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
Other Sizes |
|
靶点 |
thyroid hormone receptorα; thyroid hormone receptor β-1
|
---|---|
体外研究 (In Vitro) |
碘塞罗宁(T3,100 nM)钠可促进过度表达 TRβ1 的肝癌细胞增殖[1]。当甘草氨酸钠与人 β1 甲状腺激素受体 (hTRβ1) 结合时,它会改变受体的结构。生长、分化和代谢作用均受石氨酸钠调节[2]。
|
细胞实验 |
制备去甲状腺激素 (Td) 血清。肝癌细胞在甲基纤维素中生长。第 0 天,细胞以 3 × 104 个细胞/60 mm 培养皿的密度铺板,并在含有 5% 常规血清、5% Td 或 5% Td 和 100 nM T3 的培养基中孵育。这样做是为了确定碘塞罗宁 (T3) 对细胞生长的影响。初次铺板后三周,对甲基纤维素集落形成进行评分[1]。
|
参考文献 |
|
分子式 |
C15H11I3NNAO4
|
---|---|
分子量 |
672.9553
|
精确质量 |
672.7720
|
元素分析 |
C, 26.77; H, 1.65; I, 56.57; N, 2.08; Na, 3.42; O, 9.51
|
CAS号 |
55-06-1
|
相关CAS号 |
Liothyronine;6893-02-3;Liothyronine sodium hydrate;345957-19-9;Liothyronine hydrochloride;6138-47-2
|
外观&性状 |
White to off-white solid powder
|
SMILES |
C1=CC(=C(C=C1OC2=C(C=C(C=C2I)C[C@@H](C(=O)[O-])N)I)I)O.[Na+]
|
InChi Key |
SBXXSUDPJJJJLC-YDALLXLXSA-M
|
InChi Code |
InChI=1S/C15H12I3NO4.Na/c16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22;/h1-4,6,12,20H,5,19H2,(H,21,22);/q;+1/p-1/t12-;/m0./s1
|
化学名 |
sodium;(2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoate
|
别名 |
Liothyronine; Cytomel; Tertroxin; Triiodothyronine; 3,5,3'-triiodothyronine; 3,3',5-Triiodo-L-thyronine; Tresitope; Liothyronin
|
HS Tariff Code |
2934.99.9001
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
0.1 M NaOH: ~12.5 mg/mL (~18.6 mM)
DMSO: ~5.6 mg/mL (~8.3 mM) H2O: < 0.1 mg/mL) |
---|---|
溶解度 (体内) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.71 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.71 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.71 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 1.4860 mL | 7.4299 mL | 14.8597 mL | |
5 mM | 0.2972 mL | 1.4860 mL | 2.9719 mL | |
10 mM | 0.1486 mL | 0.7430 mL | 1.4860 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT04115514 | Recruiting | Drug: Liothyronine Sodium (T3) (modified formulation) |
Lung, Wet Thyroid |
University of Minnesota | October 21, 2019 | Phase 2 |
NCT01800617 | Completed | Drug: Liothyronine, Sodium | Hypothyroidism | Ipe, LLC | March 2013 | Phase 2 |
NCT01153360 | Completed | Drug: liothyronine sodium Drug: placebo |
Non-thyroidal Illness Syndrome | Yonsei University | June 2010 | Not Applicable |
NCT01581463 | Completed | Drug: Liothyronine, Sodium | Healthy | Ipe, LLC | April 2012 | Phase 1 |
NCT02760056 | Completed | Drug: Liothyronine sodium Drug: Placebo |
Multiple Sclerosis | Oregon Health and Science University |
June 6, 2016 | Phase 1 |